文献速递血管炎

BVAS与FFS评估ANCA相关血管炎生存预后的比较:西班牙REVAS注册研究550例

Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score to Assess Survival in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Study of 550 Patients From Spain (REVAS Registry).
PubMed 文献 · Arthritis Care Res (Hoboken) · 2020-06-12

该研究基于西班牙REVAS注册库550例ANCA相关血管炎(AAV)患者,比较BVAS第3版与FFS 1996版及2009版对生存的预测准确性。结果显示总体死亡率为33.1%,2009版FFS为最强预测因子(HR 2.9,95%CI 2.4-3.6),ROC曲线下面积达0.74,优于BVAS(0.60)和1996版FFS(0.65)。

要点

  • 2009版FFS对AAV生存预测准确性最优,AUC 0.74,优于BVAS和1996版FFS。
  • BVAS、1996版FFS和2009版FFS均与死亡显著相关,但2009版FFS预测力最强。
  • 2009版FFS与BVAS相关性较弱(r=0.28),提示二者评估维度不同。

核心结论

  • BVAS和FFS均可预测AAV生存,但2009版FFS在疾病任何阶段的预后准确性均最佳。

研究设计与样本

  • 基于西班牙REVAS注册库的回顾性研究,纳入1990至2016年诊断的550例AAV患者,其中肉芽肿性多血管炎占41.1%、显微镜下多血管炎占37.3%、嗜酸性肉芽肿性多血管炎占21.6%。

主要发现

  • 总体死亡率为33.1%,非幸存者的BVAS、1996版FFS和2009版FFS均值均显著高于幸存者(P<0.001)。
  • 多变量分析显示BVAS(P=0.007)、1996版FFS(P=0.020)和2009版FFS(P<0.001)均与死亡显著相关。
  • 2009版FFS为最强预测因子,风险比(HR)为2.9(95%CI 2.4-3.6)。
  • ROC分析显示BVAS、1996版FFS和2009版FFS的曲线下面积分别为0.60、0.65和0.74。
  • BVAS与1996版FFS相关性中等(r=0.49,P<0.001),与2009版FFS相关性较弱(r=0.28,P<0.001)。

关键数值与推荐

  • 2009版FFS的AUC为0.74,高于BVAS的0.60和1996版FFS的0.65。
  • 2009版FFS预测死亡的HR为2.9(95%CI 2.4-3.6)。

临床怎么用

  • 在AAV患者预后评估中,可优先采用2009版FFS进行生存风险分层,其预测准确性优于BVAS和1996版FFS。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the accuracy of the Birmingham Vasculitis Activity Score (BVAS), version 3, and the Five Factor Score (FFS), version 1996 and version 2009, to assess survival in antineutrophil cytoplasmic antibody-associated vasculitis (AAV). METHODS: A total of 550 patients with AAV (41.1% with granulomatosis with polyangiitis, 37.3% with microscopic polyangiitis, and 21.6% with eosinophilic granulomatosis with polyangiitis), diagnosed between 1990 and 2016, were analyzed. Receiver operating characteristic (ROC) curves and multivariable Cox analysis were used to assess the relationships between the outcome and the different scores. RESULTS: Overall mortality was 33.1%. The mean ± SD BVAS at diagnosis was 17.96 ± 7.82 and was significantly higher in nonsurvivors than in survivors (mean ± SD 20.0 ± 8.14 versus 16.95 ± 7.47, respectively; P < 0.001). The mean ± SD 1996 FFS and 2009 FFS were 0.81 ± 0.94 and 1.47 ± 1.16, respectively, and were significantly higher in nonsurvivors than in survivors (mean ± SD 1996 FFS 1.17 ± 1.07 versus 0.63 ± 0.81 [P < 0.001] and 2009 FFS 2.13 ± 1.09 versus 1.15 ± 1.05 [P < 0.001], respectively). Mortality rates increased according to the different 1996 FFS and 2009 FFS categories. In multivariate analysis, BVAS, 1996 FFS, and 2009 FFS were significantly related to death (P = 0.007, P = 0.020, P < 0.001, respectively), but the stronger predictor was the 2009 FFS (hazard ratio 2.9 [95% confidence interval 2.4-3.6]). When the accuracy of BVAS, 1996 FFS, and 2009 FFS to predict survival was compared in the global cohort, ROC analysis yielded area under the curve values of 0.60, 0.65, and 0.74, respectively, indicating that 2009 FFS had the best performance. Similar results were obtained when comparing these scores in patients diagnosed before and after 2001 and when assessing the 1-year, 5-year, and long-term mortality. Correlation among BVAS and 1996 FFS was modest (r = 0.49; P < 0.001) but higher than between BVAS and the 2009 FFS (r = 0.28; P < 0.001). CONCLUSION: BVAS and FFS are useful to predict survival in AAV, but the 2009 FFS has the best prognostic accuracy at any point of the disease course.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Solans-Laqué R, Rodriguez-Carballeira M, Rios-Blanco JJ, et al. Comparison of the Birmingham Vasculitis Activity Score and the Five-Factor Score to Assess Survival in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Study of 550 Patients From Spain (REVAS Registry). Arthritis Care Res (Hoboken). 2020. PMID: 31033198. doi:10.1002/acr.23912

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。